{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29","upperLimit":"72","value":"48"}]}],"title":"Grade II-IV Acute GVHD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10","upperLimit":"47","value":"23"}]}],"title":"Grade III-IV Acute GVHD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34","upperLimit":"78","value":"55"}]}],"title":"Chronic GVHD"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"Incidence of acute (Stage II-IV and Stage III-IV) and chronic GVHD (any stage) were analyzed.\n\nAcute GVHD Grading:\n\nStage II - Skin, 25-50% BSA (Body Surface Area); Liver, 3.1-6mg/dl bilirubin; Gut, 1000-1500ml/day diarrhea Stage III - Skin, generalized erythroderma; Liver, 6.1-15mg/dl bilirubin; Gut, \\>1500ml/day diarrhea Stage IV - Skin, bullae; Liver, \\>15mg/dl bilirubin; Gut, pain +/- ileus","dispersionType":"95% Confidence Interval","groups":[{"description":"Fludarabine Busulfan chemotherapy regimen(Flu-Bu4), followed by allogeneic stem cell transplant from best available, matched donor.\n\nFludarabine/Busulfan x 4 days:\n\nFludarabine: 40 mg/m2/day in NS, administered IV over 30 minutes on days -5, -4, -3, and -2 pre-transplant.\n\nBusulfan: 3.2 mg/kg IV daily in NS over 4 hours on days -5, -4, -3, and -2.\n\nThe Fludarabine shall be administered prior to the Busulfan each day.","id":"OG000","title":"Flu-Bu4"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"100 days, 2 years","title":"Percentage of Patients With Acute and Chronic Graft Versus Host Disease (GVHD)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}